Comparing adolescent glomerular disease clinical outcomes to the clinical outcomes in childhood, young adult, and adult-onset glomerular disease in the CureGN database
Approximately 25% of each age cohort reached the composite eGFR decline outcome within 5 years. As more glomerular disease clinical trials become available, we must consider opening these trials to people with childhood and adolescent onset disease since like adults they are at high risk of progressive kidney function decline.
Authors
- Eloise Salmon (ORCID: https://orcid.org/0000-0003-0974-3719)
- Susan F. Massengill (ORCID: https://orcid.org/0000-0002-3048-6983)
- Nathaniel Putnam
- Rachana Srivastava (ORCID: https://orcid.org/0000-0002-5325-5555)
- Myda Khalid (ORCID: https://orcid.org/0000-0002-0613-3790)
- Kelly Garrity (ORCID: https://orcid.org/0000-0003-3897-0099)
- Jeremy D. Isaacs (ORCID: https://orcid.org/0000-0002-2745-9597)
- Elaine S. Kamil
Institutions
- Cedars-Sinai Medical Center (US)
- Albert Einstein College of Medicine (US)
- Medical University of South Carolina (US)
- University of Michigan (US)
- Riley Hospital for Children (US)
- Levine Children's Hospital (US)
- Mattel Children's Hospital (US)
- Children's Hospital at Montefiore (US)
- Indiana University School of Medicine
- Indiana University – Purdue University Indianapolis (US)
Publication Details
- Journal
- Pediatric Nephrology
- Published
- 2024-12-27
- DOI
- https://doi.org/10.1007/s00467-024-06566-4
- Citations
- 4
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 1.36
Funders
- Medical University of South Carolina